Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.008
Sell
RSI(14)
40.107
Neutral
STOCH(KDJ)(9,3,3)
39.051
Neutral
ATR(14)
0.052
Low Volatility
CCI(14)
-66.111
Neutral
Williams %R
72.054
Sell
TRIX(12,20)
-0.754
Sell
StochRSI(14)
48.639
Sell
Search
Mustang Bio Inc
MBIOAdd to Watchlist
0.570USD
-0.024-3.97%
Close 07-31 16:00（ET）Quotes delayed by 15 min
4.32MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-3.97%
5 Days
+1.46%
1 Month
-18.77%
6 Months
-40.91%
Year to Date
-41.88%
1 Year
-62.73%
Key Figures
0.597Open
0.618High
11.07KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.15%Turnover Ratio
0.594Prev. Close
0.560Low
4.43KTurnover
LossP/E Static
0.50P/B
0.00%Div Yield TTM
-17.29%ROA
7.00052wk High
0.28Volume Ratio
-15.75MNet Profit
7.58MShares
-0.4798EPS TTM
2.08Beta
-44.62%ROE
0.53152wk Low
9.73%Amplitude
--Gross Margin
4.32MMarket Cap
-3.12Reward/Risk
4.97%Risk Rate
TradingKey Stock Score of Mustang Bio Inc
Currency: USD Updated: 2026-07-31Key Insights
Mustang Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 196 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mustang Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Mustang Bio Inc Highlights
StrengthsRisks
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Undervalued
The company’s latest PE is -1.19, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 664.20K shares, increasing 22.79% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Mustang Bio Inc News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.587
Sell
MA10
0.593
Sell
MA20
0.635
Sell
MA50
0.671
Sell
MA100
0.717
Sell
MA200
0.927
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mustang Bio Inc Info
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Ticker SymbolMBIO
CompanyMustang Bio Inc
CEOLitchman (Manuel)
Websitehttps://www.mustangbio.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Mustang Bio Inc (MBIO)?
The current price of Mustang Bio Inc (MBIO) is 0.57.
What is the symbol of Mustang Bio Inc?
The ticker symbol of Mustang Bio Inc is MBIO.
What is the 52-week high of Mustang Bio Inc?
The 52-week high of Mustang Bio Inc is 7.00.
What is the 52-week low of Mustang Bio Inc?
The 52-week low of Mustang Bio Inc is 0.53.
What is the market capitalization of Mustang Bio Inc?
The market capitalization of Mustang Bio Inc is 4.32M.
What is the Earnings Per Share (EPS TTM) of Mustang Bio Inc (MBIO)?
The Earnings Per Share (EPS TTM) of Mustang Bio Inc (MBIO) is -0.39.